Kasuga M, Sakita M, Yamane T, Torii T, Imai H, Kageyama N, Fujita Y, Majima S
Gan To Kagaku Ryoho. 1982 Dec;9(12):2113-21.
The purposes of this work were twofold: firstly to determine whether intratumor chemoimmunotherapy was more effective than either treatment alone or systemic therapy and; secondly to study how the intratumor therapy affected on the development of the tumor-specific immunity. Inbred male C3H/He mice and mouse ascited hepatoma 134 (MH 134) of C3H origin were used as host-tumor system. Mitomycin C was used as the chemotherapeutic agent and BCG as the immunopotentiating agent. Intratumor treatment of MMC + BCG led to complete cure in 85 percent of the mice. The lymph node metastases were markedly inhibited in the group treated with MMC + BCG compared to the groups treated with MMC alone or BCG alone. The growth of rechallenged tumor was investigated; 79% of mice treated with MMC + BCG were immune to rechallenge, whereas 57% of mice treated with BCG alone. The number of PFC and DTH against SRBC of the mice treated with MMC intraperitoneally significantly decreased compared to that treated with MMC intratumorally.
首先，确定肿瘤内化学免疫疗法是否比单独的任何一种治疗或全身治疗更有效；其次，研究肿瘤内治疗如何影响肿瘤特异性免疫的发展。近交系雄性C3H/He小鼠和源自C3H的小鼠腹水肝癌134（MH 134）被用作宿主-肿瘤系统。丝裂霉素C用作化疗药物，卡介苗用作免疫增强剂。肿瘤内注射MMC + BCG可使85%的小鼠完全治愈。与单独使用MMC或单独使用BCG治疗的组相比，MMC + BCG治疗组的淋巴结转移明显受到抑制。对再次接种肿瘤的生长情况进行了研究；接受MMC + BCG治疗的小鼠中有79%对再次接种有免疫力，而单独接受BCG治疗的小鼠中这一比例为57%。与肿瘤内注射MMC治疗的小鼠相比，腹腔注射MMC治疗的小鼠针对SRBC的PFC数量和DTH显著减少。
